<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To test the safety and efficacy of exenatide once weekly (EQW) compared with <z:chebi fb="0" ids="6801">metformin</z:chebi> (MET), <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (PIO), and <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Patients were randomized to subcutaneous (SC) EQW 2.0 mg + oral placebo (n = 248), MET 2,000 mg/day + SC placebo (n = 246), PIO 45 mg/day + SC placebo (n = 163), or SITA 100 mg/day + SC placebo (n = 163) for 26 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>MET and PIO therapies were increased to maximum-tolerated dosages </plain></SENT>
<SENT sid="3" pm="."><plain>Injections with EQW or placebo were administered weekly, while oral medication or placebo was administered daily </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Baseline characteristics were as follows: 59% men, 67% Caucasian, mean age 54 years, HbA(1c) 8.5%, fasting serum <z:chebi fb="105" ids="17234">glucose</z:chebi> 9.9 mmol/L, body weight 87.0 kg, and <z:mp ids='MP_0002055'>diabetes</z:mp> duration 2.7 years </plain></SENT>
<SENT sid="5" pm="."><plain>HbA(1c) reductions (%) at 26 weeks (least-squares means) with EQW versus MET, PIO, and SITA were -1.53 vs. -1.48 (P = 0.620), -1.63 (P = 0.328), and -1.15 (P &lt; 0.001), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Weight changes (kg) were -2.0 vs. -2.0 (P = 0.892), +1.5 (P &lt; 0.001), and -0.8 (P &lt; 0.001), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Common adverse events were as follows: EQW, <z:hpo ids='HP_0002018'>nausea</z:hpo> (11.3%) and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (10.9%); MET, <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (12.6%) and <z:hpo ids='HP_0002315'>headache</z:hpo> (12.2%); PIO, <z:e sem="disease" ids="C0027441" disease_type="Disease or Syndrome" abbrv="">nasopharyngitis</z:e> (8.6%) and <z:hpo ids='HP_0002315'>headache</z:hpo> (8.0%); and SIT, <z:e sem="disease" ids="C0027441" disease_type="Disease or Syndrome" abbrv="">nasopharyngitis</z:e> (9.8%) and <z:hpo ids='HP_0002315'>headache</z:hpo> (9.2%) </plain></SENT>
<SENT sid="8" pm="."><plain>Minor (confirmed) <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> was rarely reported </plain></SENT>
<SENT sid="9" pm="."><plain>No major <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> occurred </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: EQW was noninferior to MET but not PIO and superior to SITA with regard to HbA(1c) reduction at 26 weeks </plain></SENT>
<SENT sid="11" pm="."><plain>Of the agents studied, EQW and MET provided similar improvements in glycemic control along with the benefit of weight reduction and no increased risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
</text></document>